TY - JOUR
T1 - Association of Angiotensin Receptor Blockers with Incident Parkinson Disease in Patients with Hypertension
T2 - A Retrospective Cohort Study
AU - Lin, Hsiu Chen
AU - Tseng, Yuan Fu
AU - Shen, Ai Ling
AU - Chao, Jane Chen Jui
AU - Hsu, Chien Yeh
AU - Lin, Hsiu Li
N1 - Funding Information:
This study is based on data from the National Health Insurance Research Database provided by the National Health Insurance Administration. Our interpretations and conclusions contained herein do not represent those of the National Health Insurance Administration. Funding: None.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Background: Angiotensin receptor blockers (ARBs), which are commonly used antihypertensives, have been proposed to lower the risk of Parkinson disease by reducing oxidative stress based on animal and in vitro studies. Thus, this study aimed to test this association in patients with newly diagnosed hypertension. Methods: This retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension between 2001 and 2013. The hazard ratios for Parkinson disease were calculated for ARB treatment compared with those who never used ARBs and among the 5 subgroups receiving different cumulative ARB dosages. Results: We identified 527 (1.1%) Parkinson disease cases among patients with ARB treatment in a median observation period of 8.4 years compared to the 1,255 (2.2%) Parkinson disease cases among those without ARB treatment in a median observation period of 6.8 years. Overall, risk for developing Parkinson disease was statistically lower in the ARB-treated group with a hazard ratio of 0.56 (95% confidence interval: 0.51-0.63) than those without ARB. Conclusions: ARB treatment was associated with a statistically important reduction of Parkinson disease risk in patients with newly diagnosed hypertension. Therefore, ARB may constitute an effective neuroprotective strategy to lower Parkinson disease risk in such patients.
AB - Background: Angiotensin receptor blockers (ARBs), which are commonly used antihypertensives, have been proposed to lower the risk of Parkinson disease by reducing oxidative stress based on animal and in vitro studies. Thus, this study aimed to test this association in patients with newly diagnosed hypertension. Methods: This retrospective cohort study enrolled 107,207 patients with newly diagnosed hypertension between 2001 and 2013. The hazard ratios for Parkinson disease were calculated for ARB treatment compared with those who never used ARBs and among the 5 subgroups receiving different cumulative ARB dosages. Results: We identified 527 (1.1%) Parkinson disease cases among patients with ARB treatment in a median observation period of 8.4 years compared to the 1,255 (2.2%) Parkinson disease cases among those without ARB treatment in a median observation period of 6.8 years. Overall, risk for developing Parkinson disease was statistically lower in the ARB-treated group with a hazard ratio of 0.56 (95% confidence interval: 0.51-0.63) than those without ARB. Conclusions: ARB treatment was associated with a statistically important reduction of Parkinson disease risk in patients with newly diagnosed hypertension. Therefore, ARB may constitute an effective neuroprotective strategy to lower Parkinson disease risk in such patients.
KW - Angiotensin receptor blocker
KW - Hypertension
KW - National Health Insurance Research Dataset
KW - Parkinson disease
KW - Renin-angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=85131791125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131791125&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2022.04.029
DO - 10.1016/j.amjmed.2022.04.029
M3 - Article
C2 - 35580718
AN - SCOPUS:85131791125
SN - 0002-9343
VL - 135
SP - 1001
EP - 1007
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 8
ER -